血管软化丸调控微小RNA-21及抗动脉粥样硬化的作用机制研究

Mechanism of Xueguan Ruanhua Pills in Regulating microRNA-21 and Anti-atherosclerosis

目的观察血管软化丸抗动脉粥样硬化的作用机制,探讨是否与调控微小RNA-21(miRNA-21)和炎性因子水平有关。方法入选60例颈动脉粥样硬化病人,按照随机数字表法分为观察组和对照组,每组30例。对照组采用辛伐他汀治疗,观察组采用血管软化丸治疗。观察两组治疗前和治疗2个月后血清miRNA-21 mRNA的表达、血细胞比容、血清炎性因子水平、血管内皮功能损伤和颈动脉粥样硬化相关指标变化。结果治疗后,观察组miRNA-21 mRNA表达水平、血细胞比容和血清白介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)等炎性因子水平较治疗前比较降低,且较对照组也明显降低(P<0.05),观察组血管内皮功能损伤明显改善,且改善程度优于对照组(P<0.05),观察组颈动脉粥样硬化程度较对照组减轻(P<0.05)。结论血管软化丸治疗动脉粥样硬化可能与调控miRNA-21,进而调控血细胞比容,降低IL-10、TNF-α、IL-6等炎性因子水平,改善血管内皮功能有关。

Objective To observe the anti-atherosclerotic mechanism of Xueguan Ruanhua pills(XRP),and explore whether it was related to the regulation of microRNA-21(miRNA-21)and inflammatory factors.Methods Sixty patients with carotid atherosclerosis were randomly divided into two groups:the control group(n=30)treated with simvastatin,and the observation group(n=30)treated with XRP for 2 months.Serum miRNA-21 mRNA expression,hematocrit,serum inflammatory factors levels,vascular endothelial function injury,and carotid atherosclerosis related indicators were observed before and after treatment.Results After treatment,the levels of miRNA-21 mRNA expression,hematocrit,and serum inflammatory factors such as interleukin-10(IL-10),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6)decreased in the observation group,which were lower than that in the control group(P<0.05).The vascular endothelial function injury in the observation group was significantly improved,and the degree of improvement was better than that in the control group(P<0.05).The degree of carotid atherosclerosis in the observation group was lighter than that in the control group(P<0.05).Conclusion XRP of treatment atherosclerosis may be related to the regulation of miRNA-21 mRNA,thereby regulating hematocrit,reducing the levels of inflammatory factors such as IL-10,TNF-α,and IL-6,and improving vascular endothelial function.